within Pharmacolibrary.Drugs.ATC.P;

model P01BB51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.46,
    Cl             = 0.14 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007833333333333334,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Proguanil and atovaquone is a fixed-dose combination antimalarial medication indicated for the prevention and treatment of malaria, primarily caused by Plasmodium falciparum. This combination is widely approved and used today in many countries under the brand name Malarone. Atovaquone acts by inhibiting mitochondrial electron transport in parasites, and proguanil is a dihydrofolate reductase inhibitor, enhancing atovaquone efficacy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (both sexes), after oral administration of standard fixed-dose combination tablets.</p><h4>References</h4><ol><li><p>Pudney, M, et al., &amp; Woolley, JL (1999). Atovaquone and proguanil hydrochloride: a review of nonclinical studies. <i>Journal of travel medicine</i> 6 Suppl 1 S8–S12. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23573546/&quot;>https://pubmed.ncbi.nlm.nih.gov/23573546</a></p></li><li><p>Wallace, E, et al., &amp; Heard, CM (2012). Delivery of atovaquone and proguanil across sublingual membranes, in vitro. <i>Pharmaceutical development and technology</i> 17(6) 770–776. DOI:<a href=&quot;https://doi.org/10.3109/10837450.2011.580760&quot;>10.3109/10837450.2011.580760</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21612571/&quot;>https://pubmed.ncbi.nlm.nih.gov/21612571</a></p></li><li><p>Darade, A, et al., &amp; Patravale, V (2018). Atovaquone oral bioavailability enhancement using electrospraying technology. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 111 195–204. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2017.09.051&quot;>10.1016/j.ejps.2017.09.051</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28974387/&quot;>https://pubmed.ncbi.nlm.nih.gov/28974387</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01BB51;
